$PBIO is projected to double this years revenue

$PBIO is projected to double this years revenue to $5 million as a result of the high demand expected for the company's BaroShear K45 instrument. Technology companies with 100% growth rates can easily trade at upwards of 10 X annual sales which could demand a $50 million dollar valuation for the company's stock. With less than 2 million shares outstanding the stock can move significantly higher from current levels in the near term as the current market capitalization is a miniscule $5.9 million. Trading at only 1 X this years forecasted sales PBIO is a very cheap stock compared with its CBD industry peers. The company previously traded on the NASDAQ for upwards of $18.00 a share and is expected to relist shortly. The CBD market is hot and valuations are soaring! PBIO is a great way to add the extraordinary growth of the CBD sector.to your portfolio. https://privateequitymarkets.us/newsletter/pb...essing-cbd